Prescription Required
Darzalex 400mg Injection is a prescription medication used for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. It contains Daratumumab (400mg), a monoclonal antibody that works by targeting and destroying cancerous plasma cells in the body. This medication is typically administered as an intravenous (IV) infusion under medical supervision in a hospital or clinical setting.
Darzalex is often used alone or in combination with other anti-cancer drugs such as bortezomib, lenalidomide, or dexamethasone. It helps slow down disease progression, improve overall survival, and enhance the quality of life in patients with multiple myeloma.
Before starting treatment with Darzalex 400mg Injection, it is important to discuss potential side effects, infusion reactions, and necessary precautions with your healthcare provider. Regular monitoring and follow-ups are required to ensure the treatment is effective and safe.
There are no known direct interactions between Darzalex 400mg Injection and alcohol. However, alcohol consumption may weaken the immune system and worsen side effects such as dizziness or nausea.
Not recommended during pregnancy as Darzalex may harm the unborn baby. Women of childbearing age should use effective contraception during treatment and for 3 months after the last dose.
Darzalex may pass into breast milk, posing potential risks to the infant. Breastfeeding mothers should consult their doctor before use.
Some patients may experience dizziness, fatigue, or vision disturbances after receiving Darzalex. Avoid driving or operating machinery if these symptoms occur.
Darzalex Injection is not known to cause kidney damage, but patients with pre-existing kidney disease should use it with caution. Regular kidney function tests may be required.
Liver function should be monitored regularly, as Darzalex may cause elevated liver enzymes in some patients.
Darzalex 400mg Injection contains Daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells. By binding to CD38, Daratumumab triggers immune system activation, leading to the destruction of cancerous plasma cells. Additionally, Darzalex reduces inflammation and suppresses tumor growth, improving treatment outcomes. It also helps enhance the body’s immune response against myeloma cells, slowing disease progression and improving survival rates.
Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. It leads to weakened bones, frequent infections, kidney problems, and anemia. Treatments like Darzalex help slow disease progression and improve quality of life.
Darzalex 400mg Injection (Daratumumab 400mg) is an approved therapy for multiple myeloma, working by targeting cancerous plasma cells. It is administered via IV infusion in a hospital setting and may be used alone or in combination with other therapies. While it offers significant benefits in disease control and survival, monitoring for infusion reactions and infections is essential.
Content Updated on
Saturday, 8 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA